Faculty of Medical Sciences, Universidade de Pernambuco, Recife, Brazil.
Department of Urology, Hospital Universitário Oswaldo Cruz, Recife, Brazil.
J Endourol. 2024 Sep;38(9):936-947. doi: 10.1089/end.2024.0060. Epub 2024 Jun 17.
The use of a ureteral access sheath (UAS) during ureteroscopy (URS) has been associated with the risk for ureteral injuries. Preoperative administration of α1-blockers presents a potential mitigator of such lesions by inducing ureteral relaxation, which may also contribute to improving other surgical outcomes. A comprehensive literature search was conducted across MEDLINE, Embase, and Cochrane databases for studies comparing preoperative α1-blockers administration its non-use in adult patients without pre-stenting undergoing URS. Binary outcomes were evaluated using risk ratios (RRs) and odds ratios (ORs) with 95% confidence intervals (CIs). Heterogeneity was measured with the Cochran's Q test, statistics, and prediction intervals (PIs). A DerSimonian and Laird random-effects model was utilized for all outcomes. Eleven studies encompassing 1074 patients undergoing URS were included, of whom 522 (48.60%) received α1-blockers before the procedure. Preoperative α1-blockers were associated with a reduction in significant ureteral injuries (RR 0.30; 95% CI 0.17-0.53; = 6%; PI 0.10-0.88) and an increase in mean successful UAS insertion (OR 2.14; 95% CI 1.08-4.23; = 23%; PI 0.51-8.93). In patients undergoing exclusively ureteroscopy lithotripsy (URSL), the medications also reduced total complications (RR 0.62; 95% CI 0.46-0.84; = 0%) and complications graded Clavien-Dindo III or higher (RR 0.16; 95% CI 0.04-0.69; = 0%), but no significant difference between groups was found in the stone-free rate (RR 1.10; 95% CI 0.86-1.40; = 91%; PI 0.47-2.59). Preoperative α1-blockers were linked to a decrease in significant ureteral injuries with UAS use and fewer complications during URSL procedures. However, their impact on the successful insertion of a UAS remains uncertain. Consideration of administering preoperative α1-blockers in non-stented adult patients undergoing URS with UAS is advisable.
在输尿管镜检查 (URS) 中使用输尿管.access 鞘 (UAS) 与输尿管损伤的风险有关。术前给予 α1 受体阻滞剂可通过诱导输尿管松弛来减轻此类损伤,这也可能有助于改善其他手术结果。
对 MEDLINE、Embase 和 Cochrane 数据库进行了全面的文献检索,以比较接受 URS 治疗且未预先放置支架的成年患者术前使用和不使用 α1 受体阻滞剂的研究。使用风险比 (RR) 和优势比 (OR) 及其 95%置信区间 (CI) 评估二项结局。使用 Cochran's Q 检验、I 2 统计量和预测区间 (PI) 来测量异质性。对于所有结局,均采用 DerSimonian 和 Laird 随机效应模型。
共纳入 11 项研究,包含 1074 例接受 URS 治疗的患者,其中 522 例(48.60%)在术前接受了 α1 受体阻滞剂治疗。术前使用 α1 受体阻滞剂可降低显著的输尿管损伤发生率(RR 0.30;95%CI 0.17-0.53; = 6%;PI 0.10-0.88),增加 UAS 插入的平均成功率(OR 2.14;95%CI 1.08-4.23; = 23%;PI 0.51-8.93)。对于仅接受输尿管镜碎石术 (URSL) 的患者,药物还可降低总并发症发生率(RR 0.62;95%CI 0.46-0.84; = 0%)和 Clavien-Dindo 分级 III 或更高的并发症发生率(RR 0.16;95%CI 0.04-0.69; = 0%),但两组间无结石清除率无显著差异(RR 1.10;95%CI 0.86-1.40; = 91%;PI 0.47-2.59)。
术前使用 α1 受体阻滞剂可降低 UAS 应用时的输尿管损伤发生率和 URSL 术中的并发症发生率。然而,其对 UAS 成功插入的影响仍不确定。对于接受 URS 并使用 UAS 治疗且未放置支架的成年患者,考虑术前使用 α1 受体阻滞剂是合理的。